Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Sells 2,686 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the sale, the chief accounting officer now owns 32,146 shares in the company, valued at $482,190. This represents a 7.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Travis Alvin Thompson also recently made the following trade(s):

• On Thursday, January 2nd, Travis Alvin Thompson sold 1,750 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $14.09, for a total transaction of $24,657.50.
• On Monday, November 11th, Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $25.11, for a total value of $157,088.16.

Bicycle Therapeutics Stock Down 0.1 %

BCYC stock traded down $0.01 during trading hours on Monday, hitting $14.88. The company’s stock had a trading volume of 289,310 shares, compared to its average volume of 435,603. The stock has a 50 day moving average price of $19.27 and a two-hundred day moving average price of $21.86. Bicycle Therapeutics plc has a 12 month low of $12.17 and a 12 month high of $28.67. The company has a market capitalization of $1.03 billion, a PE ratio of -4.52 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. During the same period in the prior year, the company posted ($1.26) earnings per share. Bicycle Therapeutics’s revenue for the quarter was down 50.0% on a year-over-year basis. Sell-side analysts expect that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. JMP Securities dropped their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research report on Wednesday, December 18th. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a report on Thursday, October 31st. HC Wainwright decreased their price target on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a report on Monday, December 16th. B. Riley lowered their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $35.25.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Assetmark Inc. bought a new stake in Bicycle Therapeutics during the third quarter worth approximately $34,000. GAMMA Investing LLC lifted its stake in shares of Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after buying an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after buying an additional 2,918 shares during the period. JPMorgan Chase & Co. grew its stake in Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after buying an additional 1,782 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Bicycle Therapeutics in the 2nd quarter worth $206,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.